Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence

Share :
Published: 2 Jun 2014
Views: 4982
Prof Kevin Harrington - Institute of Cancer Research, London, UK

Prof Harrington talks to ecancertv at ASCO 2014 about a phase III study of adjuvant postoperative lapatinib with concurrent chemotherapy and radiation therapy in high-risk patients with squamous cell carcinoma of the head and neck.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.